| First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics B Wu, K Kulkarni, S Basu, S Zhang, M Hu Journal of pharmaceutical sciences 100 (9), 3655-3681, 2011 | 351 | 2011 |
| Glucuronidation: Driving Factors and Their Impact on Glucuronide Disposition G Yang, S Ge, R Singh, S Basu, K Shatzer, M Zen, J Liu, T Tu, C Zhang, ... Drug Metabolism Reviews 7, 78, 2017 | 165 | 2017 |
| Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis B Wu, S Basu, S Meng, X Wang, M Hu Current drug metabolism 12 (9), 900-916, 2011 | 123 | 2011 |
| Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro … B Sahana, K Santra, S Basu, B Mukherjee International journal of nanomedicine, 621-630, 2010 | 96 | 2010 |
| Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective AE Riedmaier, K DeMent, J Huckle, P Bransford, C Stillhart, R Lloyd, ... AAPS 22 (123), 2020 | 84 | 2020 |
| Bioavailability Challenges Associated with Development of Saponins as Therapeutic and Chemopreventive Agents. S Gao, S Basu, Z Yang, A Deb, M Hu Current drug targets, 2013 | 78 | 2013 |
| Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells XP Xie Q, Fan F, Wei W, Liu Y, Xu Z, Zhai L, Qi Y, Ye B, Zhang Y, Basu S ... Scientific Reports 7, 2017 | 53 | 2017 |
| Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a … S Basu, M Zeng, T Yin, S Gao, M Hu Journal of Chromatography B 1015, 34-41, 2016 | 45 | 2016 |
| Disposition of Flavonoids via Recycling: Direct Biliary Excretion of Enterically or Extrahepatically Derived Flavonoid Glucuronides M Zeng, R Sun, S Basu, Y Ma, S Ge, T Yin, S Gao, M Hu Molecular Nutrition & Food Research, 2016 | 45 | 2016 |
| Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study. S Basu, B Mukherjee, SR Chowdhury, P Paul International Journal of Nanomedicine 7, 6049-61, 2012 | 40 | 2012 |
| Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim S Basu, YT Lien, V Vozmediano, JF Schlender, T Eissing, ... Frontiers in Pharmacology 11 (868), 1-13, 2020 | 37 | 2020 |
| Oral Bioavailability Challenges of Natural Products Used in Cancer Chemoprevention S Gao, S Basu, A Deb, M Hu Progress in Chemistry 25 (9), 2013 | 35 | 2013 |
| Understanding mechanisms of food effect and developing reliable PBPK models using a middle-out approach XJH Pepin, JE Huckle, RV Alluri, S Basu, S Dodd, N Parrott, ... The AAPS Journal 23, 1-14, 2021 | 33 | 2021 |
| Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells Y Wei, B Wu, W Jiang, T Yin, X Jia, S Basu, G Yang, M Hu Molecular pharmaceutics 10 (5), 1736-1750, 2013 | 29 | 2013 |
| Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products S Basu, H Yang, L Fang, M Gonzalez‐Sales, L Zhao, MN Trame, L Lesko, ... Journal of Clinical Pharmacology, 1-12, 2019 | 21 | 2019 |
| Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial AF Shorr, CJ Bruno, Z Zhang, E Jensen, Gao, W, HP Feng, JA Huntington, ... Critical Care 25 (1), 354, 2021 | 20 | 2021 |
| Physiologically‐based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate N Farhan, R Cristofoletti, S Basu, S Kim, K Lingineni, S Jiang, JD Brown, ... CPT: Pharmacometrics & Systems Pharmacology 10 (3), 199-210, 2021 | 12 | 2021 |
| Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan’s Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea R Sun, S Basu, M Zeng, R Sunsong, L Li, R Ghose, W Wang, Z Liu, M Hu, ... Current Cancer Drug Targets, 2018 | 12 | 2018 |
| Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro P Mallick, S Basu, B Moorthy, R Ghose Toxicology in Vitro, 2017 | 10 | 2017 |
| Is there a paradigm shift in use of microsomes and hepatocytes in drug discovery and development? S Basu, AN Shaik ADMET and DMPK 4 (2), 114-116, 2016 | 10 | 2016 |
Zhen YangSenior Scientist, MerckVerified email at merck.com